Frankfurt - Delayed Quote EUR
Nykode Therapeutics AS (5VB.F)
As of 8:05 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-87,367.0000
-96,624.0000
-20,693.0000
1,155.0000
180,266.0000
Investing Cash Flow
6,087.0000
7,040.0000
11,050.0000
10,753.0000
-6,020.0000
Financing Cash Flow
43,689.0000
44,589.0000
360.0000
20,441.0000
-290.0000
End Cash Position
135,992.0000
162,602.0000
206,386.0000
216,231.0000
183,851.0000
Capital Expenditure
-1,086.0000
-1,902.0000
-2,675.0000
-871.0000
-99.0000
Issuance of Capital Stock
44,869.0000
45,697.0000
1,797.0000
21,182.0000
--
Free Cash Flow
-88,453.0000
-98,526.0000
-23,368.0000
284.0000
180,167.0000
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
7CA.BE Camurus AB
54.30
+4.62%
FYB.DE Formycon AG
48.35
+0.42%
THRD Third Harmonic Bio, Inc.
13.93
+4.97%
OPT Opthea Limited
4.0400
-3.12%
PHAR Pharming Group N.V.
8.31
+4.40%
SYRE Spyre Therapeutics, Inc.
37.69
+0.56%
TRVI Trevi Therapeutics, Inc.
2.9000
-6.45%
DNTH Dianthus Therapeutics, Inc.
29.90
+1.67%
HNSA.ST Hansa Biopharma AB (publ)
33.34
+3.16%
DSGN Design Therapeutics, Inc.
5.79
-2.53%